INSM
Insmed Incorporated
Biotechnology · Healthcare · United States
111.59
close · 2026-10-29
value
6
cheaper than peers6
quality
51
stronger fundamentals51
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 21.42× | 38 |
| price to book | 32.16× | 5 |
| forward P/E | 140.38× | 5 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 296.1% | 88 |
| operating margin | -23.8% | 70 |
| return on equity | -87.2% | 29 |
| debt to equity | 97.7% | 22 |
4 of 4 measures available
Facts
| market cap | $24B |
| free cash flow | -$571.8M |
| employees | 1,664 |
| first trade | 2000-06-01 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -6.42 | -5.57 | -5.34 | -3.91 |
| free cash flow | -$967.6M | -$705.8M | -$549.5M | -$410.3M |
| net income | -$1.28B | -$913.8M | -$749.6M | -$481.5M |
| revenue | $606.4M | $363.7M | $305.2M | $245.4M |
| unusual items | -$191.3M | -$38.6M | $13.8M | $30.4M |